Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Novel Mutations in AKT1 Gene in Prostate Cancer Patients in Jordan.
Alasmar A et al.
Current Issues in Molecular Biology, 2024
Working title: Molecular involvement of p53-MDM2 interactome in gastrointestinal cancers.
Yedla P et al.
Cell Biochemistry and Function, 2024
Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.
Dolgalev I et al.
Nature Communications, 2023
Discovering Deleterious Single Nucleotide Polymorphisms of Human AKT1 Oncogene: An In Silico Study.
Zhang R et al.
Life (basel, Switzerland), 2023
Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.
Mishra-Gorur K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
Carrasco R et al.
Frontiers in Oncology, 2023
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Sun H et al.
Nature Communications, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Zhang H et al.
Oncology Letters, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.
Hasbal-Celikok G et al.
Oncology Letters, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma.
Yeh YC et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
Fragoza R et al.
Nature Communications, 2019
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.
Weisner J et al.
Cancer Research, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.
Gandolfi G et al.
Oncotarget, 2018
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K et al.
Investigational New Drugs, 2017
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
AKT in cancer: new molecular insights and advances in drug development.
Mundi PS et al.
British Journal of Clinical Pharmacology, 2016
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT et al.
The Journal of Pathology, 2016
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL et al.
Bmc Cancer, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA et al.
Bmc Cancer, 2014
Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach.
Vuong H et al.
Genome Medicine, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.
Endris V et al.
The Journal of Molecular Diagnostics : Jmd, 2013
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Parikh C et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.
Ching CB et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2010
Regulation of Akt signaling activation by ubiquitination.
Yang WL et al.
Cell Cycle (georgetown, Tex.), 2010
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM et al.
Oncogene, 2010
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.
Knowles MA et al.
Cancer Metastasis Reviews, 2009